Search the Newsreel

Harmony Gold Mining (NYSE:HMY) Raised to "Buy" at Wall Street Zen

Harmonic Inc (HAM:HMC) Stock Earnings Transcripts

This GuruFocus page provides a comprehensive list of Harmonic Inc. (HAM:HMC) earnings call and other investor event transcripts, dating back to 2019. It includes transcripts for quarterly earnings, annual shareholder meetings, and participation in various technology conferences. The page also displays key financial metrics …

Harmony Biosciences (NASDAQ:HRMY) Upgraded by Wall Street Zen to "Buy" Rating

Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "hold" to a "buy" rating. The company recently reported strong quarterly earnings of $1.28 per share, surpassing estimates, with revenue increasing by 30.3% year-over-year to $261.28 million. Institutional investors hold a significant 86.23% of …

Noticias de acciones de Harmony Gold Mining Company Ltd (HMY)

The Technical Signals Behind (HLIT) That Institutions Follow

This article analyzes Harmonic Inc. (NASDAQ: HLIT) using AI models, highlighting positive near-term sentiment with a potential mid-term weak bias within a long-term strength context. It details institutional trading strategies including long, breakout, and short positions, along with multi-timeframe signal analysis and an exceptional …

Harmony Biosciences Holdings (HRMY) Could Be 19% Undervalued On Strong Q2 Earnings

Harmony Biosciences Holdings (HRMY) has shown strong performance following its Q2 2026 earnings, with increased net income and EPS, supported by WAKIX and pipeline updates. The company's share price has gained significantly over the past 90 days, and a valuation narrative suggests it is …

HLIT News | HARMONIC INC (NASDAQ:HLIT)

Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed

Harmony Biosciences Holdings, Inc. recently reported second-quarter 2026 results showing net income of US$75.43 million, up from US$39.78 million a year earlier, with basic earnings per share from continuing operations rising to US$1.30 from US$0.69. Alongside these stronger earnings, the company reported progress across …

Harmony Biosciences (NASDAQ: HRMY) holder to sell 700,883 shares

VALOR IV PHARMA HOLDINGS LLC, a shareholder of Harmony Biosciences (NASDAQ: HRMY), has filed to sell up to 700,883 shares of common stock. These shares, with an aggregate market value of $26,563,465.70, were originally acquired in 2017 through a private acquisition. The filing also …

Harmony Gold Mining Company Ltd (HMY) Stock News Today

Harmony Biosciences Holdings, Inc. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported a significant 34% EPS beat for its second quarter, with revenue also exceeding expectations. Analysts have revised their future earnings estimates upwards, projecting robust growth in the coming years. Despite these positive revisions, there are concerns regarding the …

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

Xenon Pharmaceuticals XENE reported a loss of $1.11 per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.16 per share. The company had incurred a loss of $1.07 per share in the year-ago quarter. In …

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A webcast of the event will be available on the investor page of the company's website. Harmony Biosciences focuses on …

Harmony Biosciences management plans Aug. 13 fireside chat webcast

Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A live webcast will be accessible via the investor page of the Harmony …

Dimensional Fund Advisors LP Boosts Stake in Harmonic Inc. $HLIT

Dimensional Fund Advisors LP increased its stake in Harmonic Inc. (NASDAQ:HLIT) by 5.4% in the first quarter, bringing its total holdings to 3.67 million shares valued at $33.0 million. While institutional investors own a significant portion of HLIT, analyst sentiment remains mixed with a …

Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM)

Two healthcare stocks, Harmony Biosciences Holdings (HRMY) and Beam Therapeutics (BEAM), have received bullish ratings from analysts. H.C. Wainwright reiterated a Buy rating for Harmony Biosciences with a $55.00 price target, while Beam Therapeutics holds a Strong Buy consensus with a target of $55.00, …

Harmony Biosciences Holdings, Inc. Stock 12‑Month Price Target Cut to $44.7, Implies 26% Upside

Harmony Biosciences Holdings, Inc.'s average 12-month stock price target has been reduced from $45.5 to $44.7 by 10 analysts, with individual forecasts ranging from $28 to $70 per share. This new target suggests a potential upside of approximately 26% based on the August 3rd …

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. By their very nature, these stocks carry above-average risk and volatility. …

Harmonic (HLIT) to Announce Quarterly Earnings on Wednesday

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

Harmony Biosciences Holdings, Inc. HRMY reported second-quarter 2026 earnings of $1.28 per share, up from 68 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate of 97 cents. Quarterly revenues rose 30% year over year to $261.28 million and surpassed the …

Harmony Biosciences 2Q 2026: Revenue $261.28M, EPS $1.28— 10-Q Summary

Harmony Biosciences Holdings, Inc. reported strong second-quarter 2026 results, with revenue reaching $261.28 million and diluted EPS at $1.28, significantly up from the prior year. This growth was driven by increased product volume and a price adjustment in January 2026. The company also highlighted …

Sei Investments Co. Grows Position in Harmony Gold Mining Company Limited $HMY

Sei Investments Co. significantly increased its stake in Harmony Gold Mining Company Limited (NYSE:HMY) by 22% in the first quarter, now holding over 900,000 shares valued at approximately $13.9 million. Other institutional investors like Goldman Sachs, AQR Capital Management, and Lazard Asset Management also …

Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer

Oppenheimer analyst Andreas Argyrides has lowered the price target for Harmony Biosciences Holdings Inc. (HRMY) to $70. This information was updated on August 4, 2026, at 2:30 PM EDT. The full details of this analyst action are available only to premium subscribers of StreetInsider.com.

Oppenheimer lowers Harmony Biosciences stock price target on model updates

Oppenheimer has lowered its price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) to $70 from $85, while maintaining an Outperform rating. This adjustment follows the company's strong second-quarter 2026 results, which saw Wakix net sales exceed estimates, and the reiteration of full-year 2026 guidance. …

Harmony Biosciences Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc. released its Q2 2026 earnings, reporting an EPS of $1.50, which beat estimates by $0.35. The company's revenue reached $261.28 million, surpassing expectations by $8.01 million and showing a 30.32% year-over-year increase. This presentation accompanies their earnings call for the …

Harmony Biosciences Holdings Surges 11.0% Amid Sector-Wide Rally

Harmony Biosciences Holdings (HRMY) surged 11.0% to $39.50, driven by a sector-wide rally in biotechnology stocks, with peers like AMLX and NUVB also seeing gains. The company's stock experienced elevated trading volume, adding to its market capitalization of $2.3 billion. Positive analyst sentiment, including …

Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 11.4% Following Strong Earnings

Harmony Biosciences Shares Rise After Q2 Earnings, Product Revenue Increase

Harmony Biosciences (NASDAQ: HRMY) lifts Q2 profit as WAKIX sales grow

Harmony Biosciences (HRMY) reported a significant increase in Q2 2026 profitability, with net product revenue rising to $261.28 million and net income reaching $75.43 million, driven by strong WAKIX sales. The company's pipeline includes Pitolisant GR with a PDUFA date of April 1, 2027, …

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) reported Q2 earnings of $1.28 per share, significantly beating the Zacks Consensus Estimate of $0.97, and revenues of $261.28 million, surpassing estimates by 3.46%. Despite underperforming the market year-to-date, the company holds a Zacks Rank #1 (Strong Buy) due …

(HRMY) Harmony Biosciences Expects 2026 Wakix Net Revenue Range $1.0B to $1.04B

Harmony Biosciences Holdings, Inc. (HRMY) anticipates its 2026 net revenue from Wakix to be in the range of $1.0 billion to $1.04 billion. This announcement follows recent financial updates, including Q2 EPS of $1.28 and Q2 revenue of $261.3 million, both exceeding FactSet estimates. …

Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q2 Revenue $261.3M, vs. FactSet Est of $250.8M

Harmony Biosciences Holdings, Inc. reported Q2 revenue of $261.3 million, surpassing FactSet's estimate of $250.8 million. The company, focused on therapies for rare neurological diseases, also announced its Q2 2026 earnings call and confirmed earnings results for the quarter and six months ended June …

Harmony Biosciences Holdings, Inc Q2 Profit Climbs

(RTTNews) - Harmony Biosciences Holdings, Inc (HRMY) released earnings for its second quarter that Increased, from last year The company's earnings totaled $75.43 million, or $1.28 per share. This compares with $39.78 million, or $0.68 per share, last year. The company's revenue for the …

Harmony Biosciences Announces Record Q2 2026 Revenue and

Harmony Biosciences reported record Q2 2026 revenue of $261.3 million for WAKIX, a 30% year-over-year increase, and reiterated its full-year guidance of $1.0 billion to $1.04 billion. The company also shared positive Phase 1 clinical data for its orexin-2 agonist BP-205, reinforcing its potential …

Harmony Biosciences (NASDAQ:HRMY) Announces Earnings Results, Beats Estimates By $0.32 EPS

Harmony Biosciences (HRMY) Stock Jumps On Profit Surge As Margin Pressure Lingers